Form 4: MPM BioVentures Reduces Werewolf Therapeutics Stake

MPM BioVentures, a 10% owner and director, reported multiple sales of Werewolf Therapeutics common stock totaling 209,652 shares in mid-November 2025.

Summary

• MPM BioVentures 2014, L.P., along with related entities, reported the sale of 209,652 shares of Werewolf Therapeutics, Inc. common stock.
• The sales occurred over three separate dates: November 13, 14, and 17, 2025.
• These transactions were executed under a Rule 10b5-1 trading plan established on September 24, 2025.
• On November 13, 2025, 90,951 shares were sold at a weighted average price of $0.98 per share, with prices ranging from $0.918 to $1.07.
• On November 14, 2025, 61,640 shares were sold at a weighted average price of $0.93 per share, with prices ranging from $0.895 to $0.9551.
• On November 17, 2025, 57,061 shares were sold at a weighted average price of $0.95 per share, with prices ranging from $0.9183 to $0.99.
• Following these transactions, the reporting persons collectively beneficially own 5,481,539 shares of Werewolf Therapeutics common stock.

Sentiment

Score: 3

Explanation: The sentiment is moderately negative due to a significant 10% owner and director reducing their stake, which can be perceived as a lack of confidence, despite the sales being pre-planned under a 10b5-1 plan.

Negatives

• A significant 10% owner and director, MPM BioVentures, has reduced its stake in Werewolf Therapeutics, selling a total of 209,652 shares.
• The sales occurred at prices ranging from $0.895 to $1.07, which are relatively low, potentially indicating a lack of strong conviction at current valuation levels.

Risks

• The reduction in ownership by a significant institutional investor and director could signal a perceived lack of future growth potential or increased risk by the selling entity.
• Continued selling pressure from large shareholders could negatively impact the stock price.

Future Outlook

NA

Industry Context

This filing reflects a routine disclosure of insider trading activity, common in the biotechnology sector where early investors often monetize portions of their holdings as companies mature or strategic investment horizons shift. While the sales are pre-planned, they occur in a sector sensitive to investor sentiment and capital allocation decisions.

Related Party Transactions

• The transactions involve MPM BioVentures 2014, L.P. and several related entities, which are identified as a 10% owner and director of Werewolf Therapeutics, Inc. These are sales of common stock by a related party.

Stakeholder Impact

• Shareholders: May interpret the insider selling as a negative signal, potentially leading to downward pressure on the stock price.
• Management: The sales by a director and significant owner could be a point of discussion regarding long-term commitment, though the 10b5-1 plan mitigates immediate concerns.

Key Dates

Recommendation

While the sales by a 10% owner and director are generally a negative signal, the transactions were executed under a pre-established Rule 10b5-1 plan, suggesting they are not a reaction to recent negative news. However, the consistent selling at relatively low prices by a significant insider warrants caution. Investors should hold and monitor future insider activity and company performance rather than initiating new positions or selling based solely on this filing.

Keywords

Werewolf Therapeutics, HOWL, MPM BioVentures, Insider Selling, Form 4, Equity Sales, Biotechnology, Pharmaceuticals, Institutional Investor